is tirzepatide a glp-1 Microdosing Program Tirzepatide vs Semaglutide | Understanding
Description
10.3389/fcdhc.2023.1293926 23
Supporting a role of the NTS in mediating GLP-1's effects on food intake, adeno-associated virus (AAV) mediated knock-down of GLP-1R in the NTS results in higher food intake and meal size [699]
People taking injectable semaglutide can lose on average 15 percent of their weight while a clinical trial found that more than one-third of participants on tirzepatide lost 25 percent of their weight over 72 weeks
Typically, these medications are approved for adults who meet certain criteria
The overwhelming interest in GLP-1s is prompting scrutiny of utilization patterns, clinical outcomes, and cost-effectiveness
